Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition

17th July 2019 Uncategorised 0

AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.

More: Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition
Source: News